Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Last trade$0.3794
Day change-$0.0184 (-4.63%)
Day range$0.37 – $0.406
Volume1,515,194
Market cap$77M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$77.88M
Price / earnings
—
Price / book
13.13×
Price / sales
14.32×
EV / sales
14.2×
EV / EBITDA
-1.53×
Profitability
Earnings per share
-$0.31
Return on assets
-220%
Return on equity
-1,033.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.92×
Current ratio
1.2×
Quick ratio
1.18×
Cash ratio
0.83×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$51.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LUCD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.2M
$1.47M
$1.26M
$1.5M
$1.21M
$1.16M
$828K
$1.2M
Cost of revenue
$1.4M
$1.45M
$1.63M
$1.86M
$1.7M
$1.56M
$1.55M
$2.15M
Gross profit
-$201K
$29K
-$369K
-$356K
-$486K
-$400K
-$723K
-$948K
Selling, general and administrative
$10.79M
$11.53M
$10.43M
$11.83M
$9.9M
$9.62M
$10.23M
$9.87M
Research and development
$1.18M
$1.19M
$1.21M
$1.72M
$1.27M
$1.26M
$1.43M
$1.45M
Total operating expenses
$12.08M
$12.83M
$11.75M
$13.66M
$11.27M
$10.98M
$11.76M
$11.43M
Operating income
-$12.28M
-$12.8M
-$12.11M
-$14.01M
-$11.76M
-$11.38M
-$12.49M
-$12.38M
Interest expense
-$1K
-$4K
-$6K
-$6K
-$2K
-$6K
-$9K
-$7K
Income before taxes
-$6.68M
-$11.69M
-$13.91M
-$16.27M
-$10.4M
-$4.44M
-$26.91M
-$11.54M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.68M
-$11.69M
-$13.91M
-$16.27M
-$10.4M
-$4.44M
-$26.91M
-$11.54M
Net income attributable to common shareholders
-$6.68M
-$14.72M
-$23.63M
-$16.27M
-$10.4M
-$7.89M
-$36.02M
-$11.54M
EBITDA
-$12.05M
-$12.58M
-$11.89M
-$14.04M
-$11.54M
-$11.16M
-$12.27M
-$12.4M
Basic earnings per share
-$0.03
-$0.08
-$0.17
-$0.12
-$0.10
-$0.08
-$0.52
-$0.20
Diluted earnings per share
-$0.03
-$0.08
-$0.17
-$0.12
-$0.10
-$0.08
-$0.52
-$0.20
Recent news
Company coverage with links to the original publishers.
Orthofix reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.11 by 63.64%, but revenues of $207.8 million missed expectations by 1.25%. The stock has underperformed the market significantly, down 48.1% year-to-date versus the S&P 500's 7.8% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market near-term.
Mettler-Toledo reported Q3 2026 earnings of $12.57 per share, beating consensus estimates of $12.11, with revenues of $1.09 billion exceeding expectations by 2.28%. The company has outperformed the market by 23.6% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
With U.S. crude above $100 per barrel, investors are turning to smaller companies with emerging technologies. Kraig Biocraft Laboratories shipped its first commercial spider silk order, Hyperscale Data reaffirmed 2027 revenue guidance of $300-350 million, Lucid Diagnostics began receiving Medicare payments for its EsoGuard test, and 22nd Century Group reported 66% quarterly revenue growth with improving profitability metrics.
Lucid Diagnostics Inc. (NASDAQ:LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., announced it will host a business update conference call and webcast on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog will provide a business update and discuss operations and growth strategy, while CFO Dennis McGrath will discuss fourth quarter 2025 financial results.
PAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital Market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.